title: Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.
abstract: BACKGROUND
  Adapalene is a new chemical entity that exhibits tretinoin-like activities in the terminal differentiation process.
  
  
  OBJECTIVE
  We evaluated a dose range effect of two concentrations of adapalene gel as acne treatment and compared adapalene 0.1% gel with tretinoin 0.025% gel in the treatment of acne patients in two large multicenter studies.
  
  
  METHODS
  Multicenter, investigator-masked, parallel group studies including 89 acne patients in the dose range study and 591 patients in the concurrent controlled studies were conducted.
  
  
  RESULTS
  Adapalene gel 0.1% was significantly more effective in treating acne lesions than 0.03% adapalene gel. Adapalene gel 0.1% was significantly more effective than 0.025% or tretinoin gel in one study and of the same effectiveness in the other study. Adapalene gel was always better tolerated than tretinoin gel.
  
  
  CONCLUSIONS
  Adapalene 0.1% gel is a safe and effective treatment of acne vulgaris.
authors.affiliation: General Infirmary, Leeds.
authors.forename: W J
authors.initials: WJ
authors.lastname: Cunliffe
authors.forename: R
authors.initials: R
authors.lastname: Caputo
authors.forename: B
authors.initials: B
authors.lastname: Dreno
authors.forename: L
authors.initials: L
authors.lastname: Förström
authors.forename: M
authors.initials: M
authors.lastname: Heenen
authors.forename: C E
authors.initials: CE
authors.lastname: Orfanos
authors.forename: Y
authors.initials: Y
authors.lastname: Privat
authors.forename: A
authors.initials: A
authors.lastname: Robledo Aguilar
authors.forename: J
authors.initials: J
authors.lastname: Meynadier
authors.forename: M
authors.initials: M
authors.lastname: Alirezai
authors.forename: S
authors.initials: S
authors.lastname: Jablonska
authors.forename: A
authors.initials: A
authors.lastname: Shalita
authors.forename: J S
authors.initials: JS
authors.lastname: Weiss
authors.forename: D K
authors.initials: DK
authors.lastname: Chalker
authors.forename: C N
authors.initials: CN
authors.lastname: Ellis
authors.forename: A
authors.initials: A
authors.lastname: Greenspan
authors.forename: H I
authors.initials: HI
authors.lastname: Katz
authors.forename: I
authors.initials: I
authors.lastname: Kantor
authors.forename: L E
authors.initials: LE
authors.lastname: Millikan
authors.forename: J M
authors.initials: JM
authors.lastname: Swinehart
authors.forename: L
authors.initials: L
authors.lastname: Swinyer
authors.forename: C
authors.initials: C
authors.lastname: Whitmore
authors.forename: J
authors.initials: J
authors.lastname: Czernielewski
authors.forename: M
authors.initials: M
authors.lastname: Verschoore
mesh_terms: D000068816:Adapalene; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005060:Europe; D005260:Female; D005782:Gels; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005782:Gels; D007641:Keratolytic Agents; D009281:Naphthalenes; D000068816:Adapalene; D014212:Tretinoin